Baseline Investigation of Chronic Hepatitis B Viruses Infections: Who is Eligible for Treated Criteria

NCT ID: NCT04264312

Last Updated: 2020-02-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

76220 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-28

Study Completion Date

2020-01-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Through two-stage stratified cluster sampling, investigators studied the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infection-related liver disease population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hepatitis B virus (HBV) infection is a major public health problem worldwide. China has the world's largest burden of HBV infection and will be a major contributor towards the global elimination of hepatitis B disease by 2030. While, the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infections is still unknown. In response to the above situation, Sampling applied a two-stage stratified cluster sampling design in 16 Districts and 331 Townships. Investigators wanted to know the one who is eligible for treated criteria based on community in 25 and over years old in Beijing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis B

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* older than 25 years old;
* Residents with medical insurance coverage lived in Beijing more than 6 months .

Exclusion Criteria

* Persons with pacemakers;
* Pregnant women;
* Persons with ascites;
* The one whose wound was not cured at the right upper abdomen
Minimum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wu Jiang

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wu Jiang

Director of institue for immunization and prevention of Beijing CDC

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jiang Wu

Role: STUDY_DIRECTOR

Beijing Center for Disease Prevention and Control

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Xicheng District Center for Disease Prevention and Control

Beijing, Beijing Municipality, China

Site Status

Huairou District Center for Disease Prevention and Control

Beijing, Beijing Municipality, China

Site Status

Daxing District Center for Disease Prevention and Control

Beijing, Beijing Municipality, China

Site Status

Chaoyang District Center for Disease Control and Prevention

Beijing, Beijing Municipality, China

Site Status

Dongcheng District Center for Disease Control and Prevention

Beijing, Beijing Municipality, China

Site Status

Fengtai District Center for Disease Control and Prevention

Beijing, Beijing Municipality, China

Site Status

Changping District Center for Disease Prevention and Control

Beijing, , China

Site Status

FangShan District Center for Disease Prevention and Control

Beijing, , China

Site Status

Haidian District Center for Disease Prevention and Control

Beijing, , China

Site Status

Miyun District Center for Disease Prevention and Control

Beijing, , China

Site Status

Tongzhou District Center for Disease Prevention and Control

Beijing, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BJCDCWJ202001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.